Company intelligence / Profile preview

Grintech

France

Ownership: Private
Employees: ~240
Development stage: Other

Overview

Greentech Group is a medicinal biotechnology company focused on developing natural biotech solutions for neurodegenerative diseases, chronic pain, and oncology. They operate as a GMP-certified CDMO, leveraging green, white, and blue biotechnology from plants, microbes, and algae. Their pipeline includes compounds like gamma-aminobutyric acid for neurological conditions and 10-baccatin III precursors for cancer. The company is primarily in the pre-clinical stage for its proprietary pipeline.

Therapeutic areas: OncologyNeurology
Modalities: Small MoleculeNatural ProductBiotechnology-derived compounds
Industry: Biotech

Beyond the preview

Go deeper on Grintech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grintech.

Explore the full profile